Purchase Order 75N91021P00704
Award Date
8/21/21
Potential Completion Date
8/20/26
Potential Value
$234K
Federal Agency
National Cancer Institute
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order contract awarded by the National Cancer Institute, a civilian agency within the National Institutes of Health, to Illumina, Inc. to maintain and provide preventive maintenance for an Illumina NextSeq 2000 sequencing system. The contract has a ceiling value of $48,209.00 and a performance period ending on March 19, 2026. Illumina is a manufacturer of genetic sequencing and analysis instruments and reagents, and has a history of providing such products and...
This is a firm fixed price purchase order awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Illumina, Inc. for preventative maintenance service on a government-owned Illumina NextSeq 550 DNA sequencing instrument. The contract has a potential value of $189,482.72 and a completion date of March 28, 2024. It does not have any set-aside designation. As a manufacturer of genomic sequencing instruments and reagents, Illumina has...
This firm fixed price purchase order contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services (HHS), to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The $235,228 contract provides for preventive maintenance, emergency service, and support for a government-owned Illumina NextSeq 2000 sequencing system used in support of the NCI's research...
This is a firm fixed price purchase order contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), a civilian federal agency. The contract provides for maintenance services over a 5-year period for an Illumina MiSeq and NextSeq 500 sequencing instruments, which are used to support genomic research at the NCI's Laboratory of Biochemistry and Molecular Biology. The contract has a ceiling value of $250,122.52 and was awarded to Illumina,...
This is a firm fixed-price purchase order contract awarded by the National Institute on Aging (NIA), a component of the National Institutes of Health (NIH), to Illumina, Inc. for maintenance and repair services of Illumina's NovaSeq 6000 sequencing equipment. The contract has a ceiling value of $43,380.00 and a period of performance ending on October 12, 2025. The contract was awarded on a sole-source basis, as Illumina is the original equipment manufacturer of the NovaSeq 6000 sequencer....
This firm fixed-price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute (NCI) to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The contract provides for preventive and emergency maintenance of government-owned Illumina instrumentation, including MiSeq, cBOT, Freedom EVO, and NextSeq 500 systems, utilized for genome analysis in support of NCI's cancer research....
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Illumina, Inc. for an Illumina Service Contract. The contract has a ceiling value of $72,973.00 and a period of performance through February 28, 2026. Illumina, a manufacturer of genomic sequencing and analysis instruments and reagents, will provide maintenance and support services for NIAID's Illumina sequencing systems, including NextSeq,...
This is a firm fixed price purchase order awarded by the National Institutes of Health (NIH) Clinical Center to Illumina, Inc., a manufacturer of genomic sequencing systems and related products. The $32,474.32 contract is for repair services on Illumina's NextSeq 550 sequencing system over a period ending on September 13, 2024. The award does not have a set-aside designation. Illumina has previously provided a range of sequencing instruments, reagents, and bioinformatics support to various...
This firm fixed price purchase order, awarded by the National Cancer Institute (NCI) at the National Institutes of Health (NIH), provides maintenance services for seven Illumina sequencing instruments and associated equipment. The $589,617.13 contract with Illumina, Inc., a manufacturer of genomic analysis solutions, has a performance period ending on August 31, 2026. The requirement was competed without any set-aside designation. The contract provides preventative maintenance and emergency...
This is a firm fixed price purchase order awarded by the National Institutes of Health (NIH) Clinical Center to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The contract is for a 12-month base period with a 1-year option to provide comprehensive maintenance services for an Illumina HiSeq 2500 sequencing instrument used to diagnose inherited immune disorders. The contract has a ceiling value of $96,921.00 and was awarded on a sole source basis, as...